TNFRSF12A and gastric adenocarcinoma: High TNFRSF12A expression group showed a higher TIDE score, Exclusion score, and TMB level than the low TNFRSF12A expression group, which indicated that STAD patients with high TNFRSF12A expression responded more poorly to immunotherapy.